A Phase 1 interventional study of PF-07328948 and Placebo in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-05.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is the first clinical study with PF-07328948. The safety, tolerability, and plasma pharmacokinetics and pharmacodynamics of PF-07328948 after administration of escalating, single, oral doses will be evaluated.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive up to 4 dose levels of PF-07328948 single dose and up to 2 single doses of matching placebo. Doses will be administered as oral suspensions and each dose level is to be determined.
Drug: PF-07328948 · Drug: Placebo
Participants will receive up to 4 dose levels of PF-07328948 single dose and up to 2 single doses of matching placebo. Doses will be administered as oral suspensions and each dose level is to be determined.
Drug: PF-07328948 · Drug: Placebo
Participants will receive up to 4 dose levels of PF-07328948 single dose and up to 2 single doses of matching placebo. Doses will be administered as oral suspensions and each dose level is to be determined.
Drug: PF-07328948 · Drug: Placebo
investigational drug administered orally
Placebo matching active drug administered orally
Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An adverse event is considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were flagged as TEAEs. The algorithm did not consider any events that started prior to the first dose date. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up
Number of Participants With Clinical Laboratory Abnormalities Meeting Pre-Defined Categorical Criteria Without Regard to Baseline Abnormality
Pre-defined categorical criteria for laboratory abnormalities included: lymphocytes/Leukocytes \<0.8 x lower limit of normal (LLN) or \>1.2 x upper limit of normal (ULN); Neutrophils \<0.8 x LLN; Neutrophils/Leukocytes \<0.8 x LLN; Eosinophils/Leukocytes \>1.2 x ULN; Monocytes/Leukocytes \>1.2 x ULN; Bilirubin \>1.5 x ULN; Indirect Bilirubin \>1.5 x ULN; Ketones (Scalar) ≥1; URINE Hemoglobin (Scalar) ≥1; URINE Bilirubin (Scalar) ≥1; Leukocyte Esterase (Scalar) ≥1; and Bacteria (/HPF) \>20.
Time frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up
Number of Participants With Vital Signs Abnormalities Meeting Pre-Defined Categorical Criteria
Vital signs categorical criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (≥) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP ≥ 20 mmHg.
Time frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up
Number of Participants With Abnormal Electrocardiogram (ECG) Meeting Pre-Defined Categorical Criteria
ECG categorical criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) ≥300 millisecond (msec), b) ≥25% increase when baseline is \> 200 msec or ≥50% increase when baseline is less than or equal to (≤) 200 msec. 2. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) ≥140 msec, b) ≥50% increase from baseline. 3. QTcF interval (QT corrected using the Fridericia formula): a) \>450 msec and ≤480 msec, b) \>480 msec and ≤500 msec, c) \>500 msec, d) \>30 msec and ≤60 msec increase from baseline, e) \>60 msec increase from baseline
Time frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up
Change From Baseline in Electrocardiogram (ECG) Parameters (ECG Mean Heart Rate)
Maximum increase from baseline in ECG Mean Heart Rate was reported.
Time frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up
Change From Baseline in ECG Parameters (PR Interval, QRS Duration, and QTcF Interval)
Maximum increase from baseline in PR Interval, QRS Duration, and QTcF Interval was reported.
Time frame: Day 1-8 per period, along with the 28-35 day post-final dose follow-up
Maximum Concentration Observed in Plasma (Cmax)
Maximum observed plasma PF-07328948 concentration. Observed directly from data.
Time frame: Pre-dose (0 hours) and 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing of each Period (Periods 1-4)
Time to Achieve Cmax (Tmax)
Observed directly from data as time of first occurrence.
Time frame: Pre-dose (0 hours) and 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing of each Period (Periods 1-4)
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Measured Concentration (AUClast)
Area under the plasma concentration time-curve from zero to the last measured concentration. It was determined by using linear/Log trapezoidal method.
Time frame: Pre-dose (0 hours) and 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing of each Period (Periods 1-4)
Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf)
Area under the plasma concentration-time curve from time 0 extrapolated to infinite time. AUCinf = AUClast + (Clast\*/kel), where Clast\* is the predicted plasma concentration at the last quantifiable timepoint estimated from the log-linear regression analysis, and Kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve, AUClast = Area under the plasma concentration time-curve from zero to the last measured concentration.
Time frame: Pre-dose (0 hours) and 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing of each Period (Periods 1-4)
Terminal Half-Life (t1/2) of PF-07328948
Terminal elimination half-life. t1/2 = Loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Only those data points judged to describe the terminal log linear decline will be used in the regression.
Time frame: Pre-dose (0 hours) and 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 8 hours and 12 hours post Day 1 dosing of each Period (Periods 1-4)
| Milestone | PF-07328948 10 mg, PF-07328948 30 mg, PF-07328948 100 mg, Placebo | PF-07328948 10 mg, PF-07328948 30 mg, Placebo, PF-07328948 300 mg | PF-07328948 10 mg, Placebo, PF-07328948 100 mg, PF-07328948 300 mg | Placebo, PF-07328948 30 mg, PF-07328948 100 mg, PF-07328948 300 mg | PF-07328948 750 mg, PF-07328948 F mg, PF-07328948 G mg, Placebo | Placebo, PF-07328948 F mg, PF-07328948 G mg, PF-07328948 H mg | PF-07328948 300 mg, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed) | PF-07328948 300 mg, PF-07328948 750 mg, Placebo, PF-07328948 750 mg (Fed) | PF-07328948 300 mg, Placebo, PF-07328948 1500 mg, Placebo (Fed) | Placebo, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 2 | 2 | 2 | 1 | 1 | 2 | 3 | 2 | 2 |
| Completed | 2 | 2 | 2 | 2 | 0 | 0 | 2 | 1 | 2 | 2 |
| Not completed | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An adverse event is considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the study were flagged as TEAEs. The algorithm did not consider any events that started prior to the first dose date. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| Participants | Placebo | Placebo (Fed) | PF-07328948 10 mg | PF-07328948 30 mg | PF-07328948 100 mg | PF-07328948 300 mg | PF-07328948 750 mg | PF-07328948 750 mg (Fed) | PF-07328948 1500 mg |
|---|---|---|---|---|---|---|---|---|---|
| All-causality AEs | 3 | 1 | 3 | 2 | 1 | 5 | 3 | 1 | 2 |
| Treatment-related AEs | 1 | 0 | 0 | 0 | 0 | 4 | 2 | 0 | 1 |
| All-causality SAEs | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treatment-related SAEs | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Pre-defined categorical criteria for laboratory abnormalities included: lymphocytes/Leukocytes \<0.8 x lower limit of normal (LLN) or \>1.2 x upper limit of normal (ULN); Neutrophils \<0.8 x LLN; Neutrophils/Leukocytes \<0.8 x LLN; Eosinophils/Leukocytes \>1.2 x ULN; Monocytes/Leukocytes \>1.2 x ULN; Bilirubin \>1.5 x ULN; Indirect Bilirubin \>1.5 x ULN; Ketones (Scalar) ≥1; URINE Hemoglobin (Scalar) ≥1; URINE Bilirubin (Scalar) ≥1; Leukocyte Esterase (Scalar) ≥1; and Bacteria (/HPF) \>20.
| Participants | Placebo | Placebo (Fed) | PF-07328948 10 mg | PF-07328948 30 mg | PF-07328948 100 mg | PF-07328948 300 mg | PF-07328948 750 mg | PF-07328948 750 mg (Fed) | PF-07328948 1500 mg |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Clinical Laboratory Abnormalities Meeting Pre-Defined Categorical Criteria Without Regard to Baseline Abnormality | 0 | 0 | 1 | 2 | 1 | 3 | 3 | 1 | 2 |
Vital signs categorical criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (≥) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP ≥ 20 mmHg.
| Participants | Placebo | Placebo (Fed) | PF-07328948 10 mg | PF-07328948 30 mg | PF-07328948 100 mg | PF-07328948 300 mg | PF-07328948 750 mg | PF-07328948 750 mg (Fed) | PF-07328948 1500 mg |
|---|---|---|---|---|---|---|---|---|---|
| SBP <90 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Change from baseline in SBP ≥30 mmHg decrease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change from baseline in SBP ≥30 mmHg increase | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| DBP <50 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change from baseline in DBP ≥20 decrease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change from baseline in DBP ≥20 increase | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Pulse rate < 40 bpm | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulse rate > 120 bpm | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
ECG categorical criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) ≥300 millisecond (msec), b) ≥25% increase when baseline is \> 200 msec or ≥50% increase when baseline is less than or equal to (≤) 200 msec. 2. QRS interval (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) ≥140 msec, b) ≥50% increase from baseline. 3. QTcF interval (QT corrected using the Fridericia formula): a) \>450 msec and ≤480 msec, b) \>480 msec and ≤500 msec, c) \>500 msec, d) \>30 msec and ≤60 msec increase from baseline, e) \>60 msec increase from baseline
| Participants | Placebo | Placebo (Fed) | PF-07328948 10 mg | PF-07328948 30 mg | PF-07328948 100 mg | PF-07328948 300 mg | PF-07328948 750 mg | PF-07328948 750 mg (Fed) | PF-07328948 1500 mg |
|---|---|---|---|---|---|---|---|---|---|
| PR interval ≥300 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| %Change in PR interval ≥25/50% increase | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QRS interval ≥140 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| %Change in QRS interval ≥50% increase | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF interval >450 and ≤480 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF interval >480 and ≤500 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| QTcF interval >500 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in QTcF interval >30 and ≤60 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in QTcF interval >60 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Maximum increase from baseline in ECG Mean Heart Rate was reported.
| bpm | Placebo | Placebo (Fed) | PF-07328948 10 mg | PF-07328948 30 mg | PF-07328948 100 mg | PF-07328948 300 mg | PF-07328948 750 mg | PF-07328948 750 mg (Fed) | PF-07328948 1500 mg |
|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Electrocardiogram (ECG) Parameters (ECG Mean Heart Rate) | 9.52 ± 5.179 | 12.45 ± 2.616 | 9.75 ± 2.752 | 12.88 ± 3.321 | 8.36 ± 4.821 | 16.32 ± 14.132 | 15.53 ± 3.892 | 16.32 ± 4.437 | 13.42 ± 3.845 |
Maximum observed plasma PF-07328948 concentration. Observed directly from data.
| nanogram per milliliter (ng/mL) | PF-07328948 10 mg | PF-07328948 30 mg | PF-07328948 100 mg | PF-07328948 300 mg | PF-07328948 750 mg | PF-07328948 750 mg (Fed) | PF-07328948 1500 mg |
|---|---|---|---|---|---|---|---|
| Maximum Concentration Observed in Plasma (Cmax) | 294.7 ± 111 | 1549 ± 11 | 7049 ± 18 | 19100 ± 25 | 40220 ± 33 | 37440 ± 13 | 61030 ± 44 |
Observed directly from data as time of first occurrence.
| hours (hr) | PF-07328948 10 mg | PF-07328948 30 mg | PF-07328948 100 mg | PF-07328948 300 mg | PF-07328948 750 mg | PF-07328948 750 mg (Fed) | PF-07328948 1500 mg |
|---|---|---|---|---|---|---|---|
| Time to Achieve Cmax (Tmax) | 1.10 (1.00 to 3.00) | 3.00 (1.00 to 4.00) | 2.00 (1.50 to 3.00) | 3.00 (1.50 to 4.00) | 3.02 (3.00 to 4.02) | 4.00 (2.00 to 4.03) | 3.04 (2.00 to 8.03) |
Area under the plasma concentration time-curve from zero to the last measured concentration. It was determined by using linear/Log trapezoidal method.
| nanogram*hour per milliliter (ng*hr/mL) | PF-07328948 10 mg | PF-07328948 30 mg | PF-07328948 100 mg | PF-07328948 300 mg | PF-07328948 750 mg | PF-07328948 750 mg (Fed) | PF-07328948 1500 mg |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Measured Concentration (AUClast) | 0.0000 ± NA | 4396 ± 11 | 35030 ± 23 | 110200 ± 30 | 363600 ± 24 | 409300 ± 26 | 742700 ± 24 |
Area under the plasma concentration-time curve from time 0 extrapolated to infinite time. AUCinf = AUClast + (Clast\*/kel), where Clast\* is the predicted plasma concentration at the last quantifiable timepoint estimated from the log-linear regression analysis, and Kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve, AUClast = Area under the plasma concentration time-curve from zero to the last measured concentration.
| nanogram*hour per milliliter (ng*hr/mL) | PF-07328948 10 mg | PF-07328948 30 mg | PF-07328948 100 mg | PF-07328948 300 mg | PF-07328948 750 mg | PF-07328948 750 mg (Fed) | PF-07328948 1500 mg |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUCinf) | — | — | 39050 ± 19 | 114300 ± 32 | 378000 ± 26 | 427600 ± 29 | 774600 ± 28 |
Terminal elimination half-life. t1/2 = Loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Only those data points judged to describe the terminal log linear decline will be used in the regression.
| hours (hr) | PF-07328948 10 mg | PF-07328948 30 mg | PF-07328948 100 mg | PF-07328948 300 mg | PF-07328948 750 mg | PF-07328948 750 mg (Fed) | PF-07328948 1500 mg |
|---|---|---|---|---|---|---|---|
| Terminal Half-Life (t1/2) of PF-07328948 | — | — | 11.58 ± 4.2565 | 9.941 ± 2.4980 | 16.13 ± 6.5277 | 16.90 ± 5.1749 | 15.90 ± 5.5106 |
Maximum increase from baseline in PR Interval, QRS Duration, and QTcF Interval was reported.
| msec | Placebo | Placebo (Fed) | PF-07328948 10 mg | PF-07328948 30 mg | PF-07328948 100 mg | PF-07328948 300 mg | PF-07328948 750 mg | PF-07328948 750 mg (Fed) | PF-07328948 1500 mg |
|---|---|---|---|---|---|---|---|---|---|
| Maximum increase from baseline in PR Interval (msec) | 5.15 ± 5.536 | 5.10 ± 1.414 | 2.30 ± 4.260 | 2.12 ± 2.139 | 0.80 ± 4.540 | 3.93 ± 3.215 | 6.86 ± 8.703 | 10.00 ± 5.477 | 5.73 ± 1.952 |
| Maximum increase from baseline in QRS Duration (msec) | 3.54 ± 3.227 | 10.60 ± 3.111 | 1.73 ± 2.534 | 2.44 ± 2.014 | 0.14 ± 0.969 | 4.11 ± 2.858 | 0.91 ± 3.065 | 6.20 ± 3.251 | 4.40 ± 5.303 |
| Maximum increase from baseline in QTcF Interval (msec) | 6.95 ± 5.949 | 7.40 ± 3.960 | 3.10 ± 4.900 | 3.40 ± 2.879 | 1.78 ± 6.634 | 2.84 ± 4.702 | 6.90 ± 11.844 | 1.50 ± 5.236 | 8.47 ± 8.281 |
Collected over Day 1-8 per period, along with the 28-35 day post-final dose follow-up. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/13 (0%) | 1/13 (7.7%) | 3/13 (23.1%) |
| Placebo (Fed) | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| PF-07328948 10 mg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| PF-07328948 30 mg | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| PF-07328948 100 mg | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| PF-07328948 300 mg | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| PF-07328948 750 mg | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| PF-07328948 750 mg (Fed) | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| PF-07328948 1500 mg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Event | Placebo | Placebo (Fed) | PF-07328948 10 mg | PF-07328948 30 mg | PF-07328948 100 mg | PF-07328948 300 mg | PF-07328948 750 mg | PF-07328948 750 mg (Fed) | PF-07328948 1500 mg |
|---|---|---|---|---|---|---|---|---|---|
| SeizureNervous system disorders | 1/13 | 0/2 | 0/6 | 0/5 | 0/5 | 0/12 | 0/7 | 0/5 | 0/6 |
| Event | Placebo | Placebo (Fed) | PF-07328948 10 mg | PF-07328948 30 mg | PF-07328948 100 mg | PF-07328948 300 mg | PF-07328948 750 mg | PF-07328948 750 mg (Fed) | PF-07328948 1500 mg |
|---|---|---|---|---|---|---|---|---|---|
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/13 | 1/2 | 0/6 | 0/5 | 0/5 | 0/12 | 0/7 | 0/5 | 0/6 |
| Pharyngitis streptococcalInfections and infestations | 0/13 | 0/2 | 0/6 | 0/5 | 1/5 | 0/12 | 0/7 | 0/5 | 0/6 |
| Upper respiratory tract infectionInfections and infestations | 0/13 | 0/2 | 0/6 | 1/5 | 0/5 | 0/12 | 0/7 | 0/5 | 0/6 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/13 | 0/2 | 0/6 | 0/5 | 0/5 | 0/12 | 1/7 | 1/5 | 0/6 |
| Seasonal allergyImmune system disorders | 0/13 | 0/2 | 0/6 | 1/5 | 0/5 | 0/12 | 0/7 | 0/5 | 0/6 |
| Vessel puncture site bruiseGeneral disorders | 0/13 | 0/2 | 1/6 | 0/5 | 0/5 | 0/12 | 0/7 | 0/5 | 0/6 |
| COVID-19Infections and infestations | 0/13 | 0/2 | 1/6 | 0/5 | 0/5 | 0/12 | 0/7 | 0/5 | 0/6 |
| HeadacheNervous system disorders | 1/13 | 0/2 | 1/6 | 0/5 | 0/5 | 2/12 | 0/7 | 0/5 | 0/6 |
| PresyncopeNervous system disorders | 0/13 | 0/2 | 0/6 | 0/5 | 0/5 | 0/12 | 0/7 | 0/5 | 1/6 |
| Abdominal painGastrointestinal disorders | 0/13 | 0/2 | 0/6 | 0/5 | 0/5 | 0/12 | 0/7 | 0/5 | 1/6 |
| Age, Customized(Participants) | PF-07328948 10 mg, PF-07328948 30 mg, PF-07328948 100 mg, Placebo | PF-07328948 10 mg, PF-07328948 30 mg, Placebo, PF-07328948 300 mg | PF-07328948 10 mg, Placebo, PF-07328948 100 mg, PF-07328948 300 mg | Placebo, PF-07328948 30 mg, PF-07328948 100 mg, PF-07328948 300 mg | PF-07328948 750 mg, PF-07328948 F mg, PF-07328948 G mg, Placebo | Placebo, PF-07328948 F mg, PF-07328948 G mg, PF-07328948 H mg | PF-07328948 300 mg, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed) | PF-07328948 300 mg, PF-07328948 750 mg, Placebo, PF-07328948 750 mg (Fed) | PF-07328948 300 mg, Placebo, PF-07328948 1500 mg, Placebo (Fed) | Placebo, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 18-44 years | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 3 | 0 | 0 | 13 |
| 45-60 years | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 7 |
| Sex: Female, Male(Participants) | PF-07328948 10 mg, PF-07328948 30 mg, PF-07328948 100 mg, Placebo | PF-07328948 10 mg, PF-07328948 30 mg, Placebo, PF-07328948 300 mg | PF-07328948 10 mg, Placebo, PF-07328948 100 mg, PF-07328948 300 mg | Placebo, PF-07328948 30 mg, PF-07328948 100 mg, PF-07328948 300 mg | PF-07328948 750 mg, PF-07328948 F mg, PF-07328948 G mg, Placebo | Placebo, PF-07328948 F mg, PF-07328948 G mg, PF-07328948 H mg | PF-07328948 300 mg, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed) | PF-07328948 300 mg, PF-07328948 750 mg, Placebo, PF-07328948 750 mg (Fed) | PF-07328948 300 mg, Placebo, PF-07328948 1500 mg, Placebo (Fed) | Placebo, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
| Male | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 3 | 2 | 0 | 17 |
| Ethnicity (NIH/OMB)(Participants) | PF-07328948 10 mg, PF-07328948 30 mg, PF-07328948 100 mg, Placebo | PF-07328948 10 mg, PF-07328948 30 mg, Placebo, PF-07328948 300 mg | PF-07328948 10 mg, Placebo, PF-07328948 100 mg, PF-07328948 300 mg | Placebo, PF-07328948 30 mg, PF-07328948 100 mg, PF-07328948 300 mg | PF-07328948 750 mg, PF-07328948 F mg, PF-07328948 G mg, Placebo | Placebo, PF-07328948 F mg, PF-07328948 G mg, PF-07328948 H mg | PF-07328948 300 mg, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed) | PF-07328948 300 mg, PF-07328948 750 mg, Placebo, PF-07328948 750 mg (Fed) | PF-07328948 300 mg, Placebo, PF-07328948 1500 mg, Placebo (Fed) | Placebo, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 4 |
| Not Hispanic or Latino | 3 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 1 | 2 | 16 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | PF-07328948 10 mg, PF-07328948 30 mg, PF-07328948 100 mg, Placebo | PF-07328948 10 mg, PF-07328948 30 mg, Placebo, PF-07328948 300 mg | PF-07328948 10 mg, Placebo, PF-07328948 100 mg, PF-07328948 300 mg | Placebo, PF-07328948 30 mg, PF-07328948 100 mg, PF-07328948 300 mg | PF-07328948 750 mg, PF-07328948 F mg, PF-07328948 G mg, Placebo | Placebo, PF-07328948 F mg, PF-07328948 G mg, PF-07328948 H mg | PF-07328948 300 mg, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed) | PF-07328948 300 mg, PF-07328948 750 mg, Placebo, PF-07328948 750 mg (Fed) | PF-07328948 300 mg, Placebo, PF-07328948 1500 mg, Placebo (Fed) | Placebo, PF-07328948 750 mg, PF-07328948 1500 mg, PF-07328948 750 mg (Fed) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 5 |
| Black or African American | 0 | 1 | 0 | 1 | 1 | 1 | 2 | 2 | 0 | 1 | 9 |
| Asian | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Multiple | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
| Not reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Oct 2022 to primary completion in May 2023, 6 months.
Results were first posted in Nov 2024, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-07328948